With this latest follow-on award, executed by JPEO-CBRND in coordination with the Office of the Assistant secretary of Dense for Health Affairs (OASD(HA)) and the Defense Health Agency, SAB has announced three awards currently totaling USD 72m for its rapid response capability and development of its COVID-19 therapeutic candidate, SAB-185, since March of 2020.
Previous awards were supported by JPL CBRND EB and the Biomedical Advanced Research Development Authority (BARDA), part of the Assistant secretary for Preparedness and Response at the US Department of Health and Human Services.
The expanded scope provides additional funding for clinical development and manufacturing for SAB-185, a new therapeutic targeted to SARS-CoV-2 without using human donors. Separate from the funding award, JPEO-CBRND in coordination with OASD and DHA, is providing direct funding for the first-in-human clinical trials, poised to begin this month.
In addition, the expanded scope aims to build rapid response capacity and capabilities for current and future product development from discovery through licensure.
The Rapid Response Antibody Program was initiated as a USD 27m progressive and competitive three-stage rapid response contract awarded by the US Department of Defense.
The contract called for the development of a pharmaceutical platform technology capable of rapidly and reliably producing antibody-based medical countermeasures for biological threats to accelerate the delivery of a series of potent, fully-human, antibody therapeutics.
Stage 4, "COVID-19 Pandemic Response," was awarded in April of 2020 with up to USD 9.4m in support from Biomedical Advanced Research and Development Authority (BARDA). The current additional award of USD35.6 m, brings the total to up to USD 72m.
The Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) protects the Joint Force by providing medical countermeasures and defense equipment against chemical, biological, radiological and nuclear threats.
JPEO-CBRND's goal is to enable the Joint Force to fight and win unencumbered by a CBRN environment. JPEO-CBRND facilitates the rapid response, advanced development, manufacturing and acquisition of medical solutions, such as vaccines, therapeutics, and diagnostics, to combat CBRN and emerging threats such as COVID-19.
SAB Biotherapeutics is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies.
Utilising some of the most complex genetic engineering and antibody science in the world, SAB has developed the only platform that can rapidly produce natural, highly-targeted, high-potency, human polyclonal immunotherapies at commercial scale.
The company is advancing programs in autoimmunity, infectious diseases, inflammation and oncology. SAB is rapidly progressing on a new therapeutic for COVID-19, SAB-185, fully human polyclonal antibodies targeted to SARS-CoV-2 without using human donors.
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial
AstraZeneca agrees acquisition of Icosavax
Versameb names new chairman of the board
Kling Bio appoints Dr Stefano Gullà as chief scientific officer